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Abstract
Background: The incidence of gout rises with increasing age. Management of elderly (≥65 years) gout patients
can be challenging due to high rates of comorbidities, such as renal impairment and cardiovascular disease, and
concomitant medication use. However, there is little data specifically addressing the efficacy and safety of available
urate-lowering therapies (ULT) in the elderly. The objective of this post hoc analysis was to examine the efficacy
and safety of ULT with febuxostat or allopurinol in a subset of elderly subjects enrolled in the CONFIRMS trial.
Methods: Hyperuricemic (serum urate [sUA] levels ≥ 8.0 mg/dL) gout subjects were enrolled in the 6-month,
double-blind, randomized, comparative CONFIRMS trial and randomized, 1:1:1, to receive febuxostat, 40 mg or 80
mg, or allopurinol (200 mg or 300 mg based on renal function) once daily. Flare prophylaxis was provided
throughout the study duration.
Study endpoints were the percent of elderly subjects with sUA <6.0 mg/dL at the final visit, overall and by renal
function status, percent change in sUA from baseline to final visit, flare rates, and rates of adverse events (AEs).
Results: Of 2,269 subjects enrolled, 374 were elderly. Febuxostat 80 mg was significantly more efficacious (82.0%)
than febuxostat 40 mg (61.7%; p < 0.001) or allopurinol (47.3%; p < 0.001) for achieving the primary efficacy
endpoint. Febuxostat 40 mg was also superior to allopurinol in this population (p = 0.029). In subjects with mild-
to-moderate renal impairment, significantly greater ULT efficacy was observed with febuxostat 40 mg (61.6%; p =
0.028) and febuxostat 80 mg (82.5%; p < 0.001) compared to allopurinol 200/300 mg (46.9%). Compared to
allopurinol 200/300 mg, the mean percent change in sUA from baseline was significantly greater for both
febuxostat 80 mg (p < 0.001) and febuxostat 40 mg (p = 0.011) groups. Flare rates declined steadily in all
treatment groups. Rates of AEs were low and comparable across treatments.
Conclusions: These data suggest that either dose of febuxostat is superior to commonly prescribed fixed doses of
allopurinol (200/300 mg) in subjects ≥65 years of age with high rates of renal dysfunction. In addition, in this high-
risk population, ULT with either drug was well tolerated.
Trial registration: clinicaltrials.gov NCT#00430248
Background
The average age of patients seeking care for gout in the
United States is approximately 66 years [1]. Managing
gout in the elderly (≥65 years of age) is clinically chal-
lenging as people in this demographic segment have
lower creatinine clearance, a greater frequency of
comorbidities, and are often taking multiple medications
[2]. There is a dearth of evidence-based information on
effective management of urate-lowering therapies (ULT)
in elderly patients. Available ULT options in the United
States include xanthine oxidase (XO) inhibitors, allopur-
inol, and febuxostat, as well as the uricosuric agent pro-
benecid. Probenecid is not effective in gout patients
with renal impairment [3]–30% to 60% of gout patients
have some degree of renal deficiency [4]. Allopurinol,
which has been the mainstay of chronic uric acid man-
agement, is traditionally dosed according to degree of
renal impairment [5]. Such dose decrements often lead
to reduced efficacy [6]. Febuxostat is a selective, novel,
non-purine analog XO inhibitor [7] for the treatment of
chronic hyperuricemia in patients with gout [8]. Primar-
ily metabolized in the liver [9], its pharmacokinetic and
* Correspondence: Robert.Jackson@takeda.com
Takeda Global Research & Development Centers, Inc, One Takeda Parkway,
Deerfield, Illinois 60015, USA
Jackson et al. BMC Geriatrics 2012, 12:11
http://www.biomedcentral.com/1471-2318/12/11
© 2012 Jackson et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.pharmacodynamic profiles are not affected by age or by
mild-to-moderate hepatic or renal impairment [10-12].
In this post-hoc analysis, we report the efficacy and
safety of ULT with febuxostat or allopurinol in an
elderly gout population.
Methods
The CONFIRMS trial (NCT#00430248) was a 6-month,
Phase 3, double-blind, randomized, controlled trial
(RCT) further examining the comparative urate-lowering
efficacy and safety of febuxostat and allopurinol [13].
Subjects were enrolled at 324 sites in the United States.
Institutional Review Board approval was obtained, and all
subjects provided written informed consent that con-
formed to the Declaration of Helsinki and the Health
Insurance Portability and Accountability Act prior to any
study-related procedure. A total of 2,269 subjects who
met the American College of Rheumatology criteria for
the diagnosis of gout [14] and had hyperuricemia (serum
urate [sUA] ≥8.0 mg/dL [~475 μmol/L; to convert an
sUA value from mg/dL to μmol/L, multiply by 59.48])
were enrolled. Study design and subject inclusion and
exclusion criteria have been previously described [13].
Exclusion criteria included, but were not limited to, sec-
ondary hyperuricemia, xanthinuria, severe renal impair-
ment (estimated creatinine clearance [eCLcr] <30 mL/
min, calculated by Cockcroft-Gault formula corrected for
ideal body weight[15,16]), a history of cancer within 5
years of screening, or any significant medical condition
and/or conditions that would interfere with the treat-
ment, safety, or compliance with the protocol. Subjects
were randomized 1:1:1 to receive a daily dose of either
febuxostat 40 mg, febuxostat 80 mg (Uloric
®; Takeda
Global Research & Development Center, Inc, Deerfield,
IL), or allopurinol (Apotex, Inc, Weston, FL). Subjects
randomized to allopurinol received 300 mg daily if base-
line renal function was normal (eCLcr ≥90 mL/min) or
mildly impaired (eCLcr 60 to <90 mL/min); subjects with
moderate renal impairment (eCLcr 30 to <60 mL/min)
received 200 mg daily.
Throughout the 6-month treatment period, subjects
received prophylaxis for gout flares, with either colchi-
cine (Westward Pharmaceutical Corporation, Eatontown,
NJ), 0.6 mg daily, or naproxen (Westward Pharmaceutical
Corporation, Eatontown, NJ), 250 mg twice daily. Sub-
jects with eCLcr <50 mL/min were not given naproxen.
All subjects receiving naproxen prophylaxis also received
lansoprazole 15 mg daily (Takeda Global Research &
Development Center, Inc, Deerfield, IL). If subjects could
not tolerate either colchicine or naproxen, they could be
prescribed other medications for flare prophylaxis.
The primary efficacy endpoint of CONFIRMS was the
proportion of subjects who achieved a target level of
sUA <6.0 mg/dL (~360 μmol/L) at final visit. Additional
efficacy endpoints included the proportion of subjects
with mild or moderate renal impairment with a final
sUA <6.0 mg/dL and percent change in sUA from base-
line to final visit in each treatment group. Self-reported
acute gout flares requiring treatment and adverse events
(AEs) were collected throughout the study; flares were
not considered AEs. Flares were defined as acute epi-
sodes of joint swelling, pain, exquisite tenderness and
warmth, and redness at the joint, along with the overly-
ing skin being tense, warm, shiny, and purplish or red
in color. Clinical laboratory tests were performed every
2 months. All AEs were coded using Medical Dictionary
for Regulatory Activities terminology. Flare rates were
summarized by 2-month periods. Our current analyses
assessed the primary and secondary efficacy endpoints
and safety among subjects ≥65 years of age (N = 374).
Statistical analyses of the efficacy endpoints and AE
rates have been previously described in detail [13]. In the
primary CONFIRMS analysis of the total cohort (N =
2,269), non-inferiority of febuxostat 40 mg compared to
allopurinol was demonstrated. Binomial 95% confidence
intervals (CIs) were calculated for the difference between
the 2 groups in achieving the primary efficacy endpoint.
Non-inferiority was declared if the lower limit of the 95%
CI for difference in the proportion of subjects achieving
an sUA <6.0 mg/dL at the final visit was greater than
−1 0 % .T h ed i f f e r e n c eb e t w e e nt h ef e b u x o s t a t4 0m g
group (45.2%) and the allopurinol group (42.1%) was
3.1% (95% CI:-1.9%-8.1%), thus demonstrating non-infer-
iority [13]. Last observation carried forward (LOCF) was
used to account for missing data in the primary analysis.
For subjects who prematurely discontinued the study
before the Month 6 visit, the sUA value obtained at the
last completed visit was used as the final visit. For the
primary endpoint, pairwise comparisons were made
between treatment groups shown to be non-inferior with
Fisher’s exact test. Statistical significance of mean percent
change from baseline between treatment groups was
determined using ANOVA. All primary and secondary
efficacy analyses were performed on the intent-to-treat
(ITT) population, which was defined as all randomized
subjects who had a baseline sUA ≥8.0 mg/dL and
received at least 1 dose of study drug. Safety analysis was
carried out on all randomized subjects who received at
least 1 dose of study drug.
Results
Three hundred seventy-four subjects ≥65 years of age
who met all of the inclusion and none of the exclusion
criteria were enrolled in the CONFIRMS study. Of
these, 115, 128, and 131 were randomized to receive
daily febuxostat 40 mg, febuxostat 80 mg, or allopurinol
200/300 mg, respectively. Among those randomized to
receive allopurinol, 80/131 (61.1%) subjects had
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mg daily.
Figure 1 illustrates the flow of subjects ≥65 years of
age through the study. Of the 374 subjects, 83 (22.2%)
discontinued prematurely; 28 (7.5%) discontinuations
occurred during the first 30 days. Premature disconti-
nuation rates were similar across treatment groups. The
primary reason for premature discontinuation was AEs
(n = 53; 14.2%).
Demographics, baseline characteristics, and medical his-
tories were similar across treatment groups (Table 1). Sub-
jects were predominantly male (85.8%), Caucasian (84.8%),
and obese (51.3%; body mass index ≥30 kg/m
2), with a
mean age of 71 years. Mean duration of gout was 14.6
years and mean baseline sUA was 9.4 mg/dL. Tophi and
kidney stones were present in 19.3% and 19.8% of subjects,
respectively. Mild or moderate renal impairment was
determined in 139 (37.2%) and 229 (61.2%) subjects,
respectively. Comorbidities were common; in addition to
the predominance of renal impairment, the majority of
subjects (87.2%) had some history of cardiovascular dis-
ease, inclusive of, but not limited to, hypertension (82.4%),
coronary artery disease (24.3%), cardiac arrhythmia
(21.1%), and myocardial infarction (10.7%). In addition,
59.6% of elderly subjects had a history of hyperlipidemia
and 24.6% were diabetic.
Concomitant medication use was high in this popula-
tion and comparable across treatment groups (Table 2).
Sixty percent of elderly subjects were taking at least one
medication that acted on the renin-angiotensin system,
50% were taking an antithrombotic agent, while 24%
were taking at least 1 diuretic. Colchicine was the pri-
mary gout flare prophylaxis used by elderly subjects
(83.7%), while 10.4% received naproxen. The remaining
5.9% of subjects received indomethacin, nabumetone,
prednisone, or celecoxib as flare prophylaxis.
Achievement of the primary efficacy endpoint, sUA
<6.0 mg/dL at final visit, occurred in 47.3%, 61.7%, and
82.0% of subjects in the allopurinol 200/300 mg, febuxo-
stat 40 mg, and febuxostat 80 mg groups, respectively
(Figure 2). Febuxostat 80 mg was significantly more effi-
cacious than febuxostat 40 mg or allopurinol for achiev-
ing the primary efficacy endpoint (p < 0.001 for both
comparisons). In addition, febuxostat 40 mg was super-
ior to allopurinol in this elderly gout population (p =
0.029).
In subjects with any renal impairment (mild or moder-
ate), the urate-lowering efficacies (sUA of <6.0 mg/dL at
final visit) of both febuxostat 40 mg (69/112; 61.6%) and
febuxostat 80 mg (104/126; 82.5%) were significantly bet-
ter than that of allopurinol 200/300 mg (61/130; 46.9%;
p = 0.028 vs febuxostat 40 mg; p < 0.001 vs febuxostat 80
mg). Achievement of sUA <6.0 mg/dL by renal status is
also illustrated in Figure 2. Febuxostat 80 mg was signifi-
cantly more efficacious than both febuxostat 40 mg and
allopurinol in subjects with moderate renal impairment
(p ≤ 0.001) and superior to allopurinol in subjects with
mild renal impairment (p = 0.004). Within the mild or
within the moderate renal impairment categories the per-
centage of subjects achieving final visit sUA <6.0 mg/dL
was numerically greater in the febuxostat 40 mg group
than in the allopurinol group, but the differences were
not statistically significant.
The mean percent change (±standard deviation) in sUA
from baseline to the final visit for the febuxostat 40 mg,
febuxostat 80 mg, and allopurinol 200/300 mg groups
was -36.9% (±16.8), -48.1% (±20.0), and -31.1% (±16.0),
respectively. The mean percent change in sUA from
Figure 1 Flow of Subjects Through the Study.
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Page 3 of 9Table 1 Demographics, baseline characteristics, and comorbidities
a
Variable Febuxostat 40 mg
N = 115
Febuxostat 80 mg
N = 128
Allopurinol 200/300 mg
N = 131
Gender, n (%)
Male 104 (90.4) 109 (85.2) 108 (82.4)
Female 11 (9.6) 19 (14.8) 23 (17.6)
Race, n (%)
American Indian or Alaska Native 1 (0.9) 1 (0.8) 0
Asian 2 (1.7) 4 (3.1) 5 (3.8)
Black or African American 10 (8.7) 16 (12.5) 8 (6.1)
Native Hawaiian or Other Pacific Islander 1 (0.9) 2 (1.6) 0
White 98 (85.2) 103 (80.5) 116 (88.5)
Other 3 (2.6) 2 (1.6) 2 (1.5)
Ethnicity, n (%)
Hispanic or Latino 2 (1.7) 3 (2.3) 9 (6.9)
Not Hispanic or Latino 113 (98.3) 125 (97.7) 122 (93.1)
Age (years)
Mean ± SD 70.8 ± 5.19 71.2 ± 5.22 70.1 ± 4.59
Range 65-85 65-85 65-85
Body mass index (kg/m
2)
Mean ± SD 31.0 ± 5.47 30.7 ± 5.13 31.6 ± 5.60
Range 20-48 16-49 22-48
Alcohol use, n (%)
Non-/Ex-drinker 42 (36.5) 49 (38.3) 53 (40.5)
Drinker (1-14 drinks/week) 73 (63.5) 79 (61.7) 78 (59.5)
Serum urate (mg/dL)
Mean ± SD 9.4 ± 1.14 9.5 ± 1.17 9.3 ± 1.04
Range 8-14 8-13 8-13
Years with gout
Mean ± SD 15.0 ± 11.3 14.8 ± 12.40 14.1 ± 12.44
Range 0-53 0-50 0-48
Tophi present, n (%)
No 93 (80.9) 104 (81.3) 105 (80.2)
Yes 22 (19.1) 24 (18.8) 26 (19.8)
Participated in a previous febuxostat study
b, n (%)
Yes 18 (15.7) 23 (18.0) 21 (16.0)
Prior urate lowering therapies, n (%)
No 31 (27.0) 34 (26.6) 44 (33.6)
Yes (any) 84 (73.0) 94 (73.4) 87 (66.4)
Febuxostat 17 (14.8) 21 (16.4) 18 (13.7)
Allopurinol 76 (66.1) 85 (66.4) 75 (57.3)
Probenecid 5 (4.3) 6 (4.7) 6 (4.6)
Other 4 (3.5) 4 (3.1) 3 (2.3)
Renal Function
c, n (%)
Moderately Impaired 67 (58.3) 82 (64.1) 80 (61.1)
Mildly Impaired 45 (39.1) 44 (34.4) 50 (38.2)
Normal 3 (2.6) 2 (1.6) 1 (0.8)
Medical History, n (%)
Any cardiovascular disease
d 102 (88.7) 108 (84.4) 116 (88.5)
Hypertension 98 (85.2) 102 (79.7) 108 (82.4)
Coronary artery disease 26 (22.6) 28 (21.9) 37 (28.2)
Cardiac arrhythmia 16 (13.9) 28 (21.9) 35 (26.7)
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These percent changes were significantly greater in the
febuxostat 80 mg group compared with either the
febuxostat 40 mg or allopurinol 200/300 mg groups (p <
0.001 for both comparisons) and also in the febuxostat
40 mg group compared with the allopurinol 200/300 mg
group (p = 0.011).
The proportion of subjects requiring treatment for
gout flares declined in all treatment groups during the
course of the study. In the febuxostat 40 mg and 80 mg
treatment groups, flare rates during the first 2 months
were 16.5% (19/115) and 18.0% (23/128), respectively.
During the last 2 months of treatment, rates were 9.5%
(9/95) and 6.6% (7/106), respectively. Treatment for
gout flares was required by 4.6% (6/131) of subjects in
the allopurinol 200/300 mg group during the first 2
months; this rate decreased to 0.9% (1/106) during the
last 2 months. Flare rates were significantly higher in
the febuxostat 40 mg and 80 mg groups compared with
the allopurinol group (p ≤ 0.05) during the first 2
months of the study, and in the febuxostat 40 mg group
compared with the allopurinol group (p ≤ 0.05) during
the last 2 months.
Overall, rates of AEs were low and similar across treat-
ment groups; the most frequently reported AEs were
diarrhea (9.6%), upper respiratory tract infection (7.8%),
and musculoskeletal and connective tissue signs and
symptoms (6.1%) (Table 3). Rates of abnormal liver func-
tion analyses were reported in 4.3%, 3.9%, and 2.3% of
subjects in the febuxostat 40 mg, febuxostat 80 mg, and
allopurinol 200/300 mg groups, respectively. The percen-
tage of subjects who discontinued prematurely from the
study due to abnormal liver function analyses was 0.9%,
1.6%, and 0 in the febuxostat 40 mg, febuxostat 80 mg,
and allopurinol groups, respectively. Elevated liver func-
tion tests are listed by treatment group in Table 3. No
subjects experienced concurrent elevated ALT/bilirubin,
AST/bilirubin, ALT/alkaline phosphatase, AST/alkaline
phosphatase, or ALT/AST/bilirubin levels. Serious AEs
occurred in 7.8%, 6.3%, and 11.5% of subjects in the
Table 1 Demographics, baseline characteristics, and comorbidities
a (Continued)
Diabetes 23 (20.0) 35 (27.3) 34 (26.0)
Hypercholesterolemia 15 (13.0) 10 (7.8) 17 (13.0)
Hyperlipidemia 66 (57.4) 73 (57.0) 84 (64.1)
Use of low-dose aspirin (≤325 mg daily) 48 (41.7) 52 (40.6) 49 (37.4)
aThere were no statistically significant differences among treatment groups with respect to the distribution of baseline characteristics.
bSubjects previously enrolled in prior febuxostat clinical trials were permitted to enroll in the CONFIRMS trial.
cModerate baseline renal impairment: estimated creatinine clearance (eCLcr) 30- < 60 mL/min; mild baseline renal impairment: eCLcr 60- < 90 mL/min; normal:
eCLcr ≥90 mL/min.
d Any cardiovascular disease includes myocardial infarction, percutaneous transluminal coronary angioplasty, coronary artery bypass graft procedure, coronary
artery disease, transient ischemic attack, peripheral vascular disease, cardiac arrhythmia, venous thrombotic event, valvular heart disease, congestive heart
disease, and hypertension. SD = Standard deviation
Table 2 Selected concomitant medication use among elderly subjects during the CONFIRMS trial
Febuxostat 40 mg
N = 115
Febuxostat 80 mg
N = 128
Allopurinol 200/300 mg
N = 131
n (%)
Subjects with one or more concomitant medication
Agents acting on the renin-angiotensin system
a 65 (57) 78 (61) 83 (63)
Analgesics 23 (20) 33 (26) 27 (21)
Antiinflammatory and antirheumatic products 26 (23) 32 (25) 26 (20)
Antithrombotic agents 58 (50) 65 (51) 65 (50)
Beta blockers 45 (39) 43 (34) 55 (42)
Calcium channel blockers 19 (17) 21 (16) 30 (23)
Corticosteroids for systemic use 12 (10) 21 (16) 15 (11)
Drugs for acid-related gastrointestinal disorders 23 (20) 32 (25) 34 (26)
Drugs used in diabetes 20 (17) 25 (20) 29 (22)
Diuretics 26 (23) 32 (25) 33 (25)
Lipid modifying agents 64 (56) 69 (54) 75 (57)
Other antihypertensives
b 13 (11) 4 (3) 10 (8)
aAgents acting on the renin-angiotensin system include a direct renin inhibitor, angiotensin II receptor blockers, and angiotensin-converting enzyme inhibitors.
bIncludes vasodilators, alpha-blockers, and a-adrenergic receptor agonists.
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300 mg groups, respectively. Cardiac disorders and infec-
tions were the most frequently reported serious AEs; in
the febuxostat 40 mg, febuxostat 80 mg, and allopurinol
groups, 0.9%, 1.6%, and 3.1% of subjects reported cardiac
disorders and 1.7%, 0.8%, and 3.1% reported infections
and infestations. Two subjects in this elderly population
died during the study; both were in the allopurinol
group. One subject died from hypertensive heart disease,
and the other from postsurgical complications related to
lung adenocarcinoma and lymphocytic leukemia.
Discussion
This is the first analysis of randomized, controlled clini-
cal trial data to specifically examine the efficacy and
safety of ULT with febuxostat or allopurinol in a popu-
lation of elderly gout subjects with significant propor-
tions of renal impairment and other comorbidities. In
this cohort, ULT with either dose of febuxostat (40 mg
or 80 mg) was significantly more efficacious than fixed
doses of allopurinol 200/300 mg in achieving the thera-
peutic sUA goal (<6.0 mg/dL). In the total CONFIRMS
study population, the efficacy of febuxostat 40 mg was
comparable to that of allopurinol [13]. In this analysis,
the greater efficacy of febuxostat 40 mg over allopurinol
200/300 mg can be attributed to the very high propor-
tion of elderly patients with mild or moderate renal
impairment.
Flare rates declined markedly in this group, although
they were persistently higher in either febuxostat group
compared with the allopurinol group. This may reflect
more rapid, profound urate lowering in the febuxostat
groups. The paradoxical relationship between the extent
of sUA reduction and increasing flares upon initial ULT
is well recognized [17,18]; rapid lowering of sUA leads to
mobilization of monosodium urate crystals from the
body’s urate pools, thus triggering an inflammatory
response [19]. It has also been demonstrated that the
continued use of ULT for up to 5 years leads to near
elimination of gout flares [20,21].
ULT with either febuxostat or allopurinol was well tol-
erated in this population, with AE rates similar to those
reported for the entire CONFIRMS cohort [13]. Impor-
tantly, despite the high percentage of elderly subjects
with cardiovascular disease, the rates of cardiovascular
events were low and comparable across treatment
groups. This reflects the lack of any significant differ-
ences in adjudicated cardiovascular AEs as previously
reported across treatment groups for the full CONFIRMS
population [13].
As the prevalence of gout among the elderly continues
to rise [22-24], optimal management of chronic gout and
its underlying hyperuricemia is necessary to improve
clinical outcomes and reduce healthcare utilization and
associated costs. Achievement and long-term mainte-
nance of sUA <6.0 mg/dL leads to reduction of tophi and
near-elimination of acute flares [20,21,25-27], and may
stabilize or improve renal function in gout patients [28].
Gout has been identified as an independent risk factor
for diabetes, cardiovascular disease, and all-cause and
cardiovascular-related mortality [29-34]. While ULT has
not been approved for the management of asymptomatic
hyperuricemia, recent studies have suggested the cardio-
vascular-protective impact of lowering sUA levels [35],
thereby providing potential additional clinical benefit to
properly managed gout patients.
Elderly patients have a high incidence of components
of the metabolic syndrome (hypertension, obesity, dysli-
pidemia, insulin resistance) and declining renal function,
Figure 2 Achievement of sUA <6.0 mg/dL–All Subjects
(Primary Endpoint) and by Renal Function. Data regarding the
percentage of subjects with normal renal function with sUA <6.0
mg/dL is not presented due to the low number of subjects in this
group (N = 6).
ap = 0.029 vs allopurinol;
bp ≤ 0.001 vs febuxostat 40
mg;
cp < 0.001 vs allopurinol;
dp = 0.004 vs allopurinol.
Figure 3 Mean Percent Change From Baseline In Serum Urate
at Each Scheduled Visit.
ap < 0.001 vs allopurinol;
bp < 0.001 vs
febuxostat 40 mg;
cp ≤ 0.027 vs allopurinol. Error bars represent
standard deviation.
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combined with the associated concomitant medication
use, which impacts both renal function and uric acid
[36], may further increase hyperuricemia. As a result,
elderly gout patients are more challenging to manage.
Recently, Keenan et al. [37] have documented high rates
of inappropriate prescribing patterns of gout medica-
tions related to contraindicated concomitant medica-
tions for other comorbidities. Even cardioprotective use
of low-dose aspirin (75-325 mg/day) can impair renal
function and uric acid handling in elderly patients [38].
In elderly patients on thiazide diuretics, which increase
the net reabsorption of uric acid in the proximal tubule
of the nephron [39], the adjusted relative risk for the
onset of gout, as documented by initiation of anti-gout
therapy, was 1.99 (95% CI 1.21-3.26) [40]. Gout manage-
ment can be further complicated by low therapeutic
compliance; older gout patients have suboptimal adher-
ence to ULT compared with therapies for other chronic
illnesses [41].
Retrospective analyses of managed care databases reveal
that elderly gout patients have higher all-cause healthcare
utilization and costs compared with patients without gout,
and this rises with increasing sUA [36,42,43]. Comparison
of managed care database claims of 11,935 gout patients
≥65 years of age and matched non-gout patients found
that the adjusted difference in total 12-month all-cause
healthcare costs was $3,038 (p < 0.001; 2005 USD) [42].
Gout-related costs represent approximately 6% of total
healthcare costs for elderly gout patients [42]. Along with
the expected higher rate of gout-related medication use,
Hanly et al. [36] reported that compared with age- and
sex-matched controls, elderly gout patients had signifi-
cantly higher (p < 0.0001) utilization rates of diuretics and
insulin, which can increase sUA. Higher utilization rates
(p < 0.0001) were also reported for beta-blockers, angio-
tensin-converting enzyme inhibitors, angiotensin II recep-
tor blockers, and calcium channel blockers, a reflection of
higher comorbidity rates in the gout cohort [36]. In addi-
tion, higher rates (p < 0.0001) of use of gastroprotective
agents were noted, likely due to the higher NSAID usage
for treatment of flares [36]. Additional database analyses
of 2,237 elderly gout patients have shown that among
those with higher sUA (>9.0 mg/dL), compared to patients
with well-controlled sUA (<6.0 mg/dL), there was a higher
frequency of flares, and significantly higher gout-related
($620 vs $264 per flare; p < 0.0001) and total healthcare
costs ($4,944 vs $2,389 per flare; p < 0.0001) [43].
Table 3 Most frequently reported adverse events
a and elevated serum liver function tests, by treatment group
Febuxostat 40 mg
N = 115
Febuxostat 80 mg
N = 128
Allopurinol 200/300 mg
N = 131
Total subjects reporting ≥1A E , n (%) n (%)70 (60.9) 75 (58.6) 81 (61.8)
Most frequently reported
b AEs, n (%)
Diarrhea (non infectious) 14 (12.2) 12 (9.4) 10 (7.6)
Musculoskeletal and connective tissue signs and symptoms 10 (8.7) 7 (5.5) 6 (4.6)
Upper respiratory tract infections 9 (7.8) 11 (8.6) 9 (6.9)
Neurological signs and symptoms 8 (7.0) 1 (0.8) 1 (0.8)
(Dizziness) 7 (6.1) 1 (0.8) 1 (0.8)
(Presyncope) 1 (0.9) 0 0
Joint related signs and symptoms 2 (1.7) 8 (6.3) 3 (2.3)
Lower respiratory tract and lung infections 2 (1.7) 3 (2.3) 7 (5.3)
Headaches 6 (5.2) 2 (1.6) 3 (2.3)
Nausea and vomiting 6 (5.2) 1 (0.8) 4 (3.1)
Elevated liver function tests, n/N (%)
ALT
≥2X ULN 4/106 (4) 4/117 (3) 3/115 (3)
≥3X ULN 2/106 (2) 0/117 1/115 (<1)
AST
≥2X ULN 3/106 (3) 1/117 (<1) 0/115
≥3X ULN 2/106 (2) 0/117 0/115
ALT and AST concurrently
≥3X ULN 2/106 (2) 0/117 0/115
aAEs are reported by Medical Dictionary for Regulatory Activities high-level term.
bMost frequently reported AEs are those which occurred in ≥5% of elderly subjects in any treatment group.
AE = adverse event; ALT = alanine aminotransferase; AST = aspartate aminotransferase; ULN = upper limit of normal.
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Page 7 of 9This study is not without limitations, the first of which
is its post hoc nature. Even so, the data presented here
are the first gathered from an RCT and provide evidence
for the use of febuxostat as an option for the manage-
ment of chronic grout in the elderly, particularly those
with mild or moderate renal impairment. A second lim-
itation of this analysis is the use of commonly prescribed
[44,45] fixed doses of allopurinol determined by renal
function. Guideline recommendations [46] to start with a
low dose of allopurinol and slowly titrate up are based on
an outdated, single, noncomparative study of 78 patients
with renal insufficiency who all developed severe allopur-
inol hypersensitivity [5]. Failure to achieve target sUA
with guideline-recommended doses of allopurinol has
been documented [6]. In 2 recent small trials [47,48], a
total of 81 gout patients, including those with mild or
moderate renal impairment, received increasing allopuri-
nol doses above creatinine clearance-based dosing guide-
lines, which led to improved urate-lowering efficacy
without increased toxicity. Due to the very limited data
regarding the safety of high doses of allopurinol in
patients with renal insufficiency, allopurinol dosing in
this population remains controversial [49], and we cannot
speculate whether allopurinol dose titration in the CON-
FIRMS study, and more specifically among this elderly
subgroup, would have led to improved efficacy without
increased AEs. Additional studies addressing the safety of
allopurinol dose titration with much greater numbers of
subjects with renal impairment are needed. The doses of
allopurinol used in the CONFIRMS trial reflect dosing
commonly utilized in clinical practice [44,45]; therefore,
the data presented here can be applied to real-world
management of elderly gout patients.
Optimal management can lead to relief from the clinical
manifestations of gout and possibly reduce healthcare uti-
lization. Additional analyses are needed to confirm that
proper sUA management of elderly gout patients reduces
healthcare utilization and associated costs. Our results
suggest that despite high rates of comorbidities, including
renal impairment, the hyperuricemia of elderly gout
patients may be more effectively managed with approved
doses of febuxostat, with low risk of side effects.
Conclusions
This analysis of 374 elderly gout subjects demonstrates
that ULT with febuxostat 80 mg or 40 mg once daily
leads to significantly more subjects achieving a therapeu-
tic goal of sUA <6.0 mg/dL than commonly used doses
of allopurinol (200 or 300 mg). ULT was well tolerated
despite high rates of comorbidities and concomitant
medication use. These results, along with other support-
ing data, suggest that the underlying hyperuricemia of
gout in elderly patients can be more effectively managed
with either dose of febuxostat, especially in those patients
with mild to moderate renal impairment.
Abbreviations
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